HMR's Arava May Be Ripe For Review By Cigna Soon After 6-Month Delay
Executive Summary
Hoechst Marion Roussel's arthritis immunotherapy Arava is likely to be considered for coverage by the large Cigna Healthcare prescription plan, which represents about 1% of total U.S annual drug purchases.